Reflux Esophagitis (Gastroesophageal Reflux Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Reflux Esophagitis (Gastroesophageal Reflux Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in GERD therapeutics.
  • There will be more than 300 million prevalent cases of GERD in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast.
  • The marketed drugs space for GERD comprises both novel class of potassium-competitive acid blockers (P-CABs) and conventional delayed-release proton pump inhibitors (DR-PPIs).
  • R&D activity in GERD is promising with four drugs in pre-registration stage and five in Phase III development across global markets.
  • Commercial sponsors dominate clinical trial development in GERD, with the US emerging as the key country for conducting Phase III trials.
  • In deals involving companies developing GERD assets, acquisition was the most prevalent deal type globally during past two years.
  • Scope

    GlobalData’s GERD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
  • Reasons to Buy
    • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
    • Develop business strategies by understanding the trends shaping and driving the GERD market.
    • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GERD market in the future.
    • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
    • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
    • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


    1 Preface
    1.1 Contents
    1.2 Report Scope
    1.3 List of Tables and Figures
    1.4 Abbreviations
    2 Key Findings
    3 Disease Landscape
    3.1 Disease Overview
    3.2 Epidemiology Overview
    3.3 Treatment Overview
    4 Marketed Drugs Assessment
    4.1 Leading Marketed Drugs
    4.2 Overview by Mechanism of Action
    4.3 Overview by Route of Administration
    4.4 Marketed Drugs Profiles and Sales Forecasts
    5 Pricing and Reimbursement Assessment
    5.1 Annual Therapy Cost
    5.2 Time to Pricing and Reimbursement
    6 Pipeline Drugs Assessment
    6.1 Phase III Pipeline Drugs
    6.2 Overview by Development Stage
    6.3 Overview by Molecule Type
    6.4 Overview by Mechanism of Action
    6.5 Overview by Route of Administration
    6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
    6.7 Therapy Area and Indication-specific PTSR and LoA
    7 Clinical Trials Assessment
    7.1 Historical Overview
    7.2 Overview by Phase
    7.3 Overview by Status
    7.4 Overview by Phase for Ongoing and Planned Trials
    7.5 Trials with Virtual Components
    7.6 Geographic Overview
    7.7 Single-Country and Multinational Trials by Region
    7.8 Top 20 Sponsors with Breakdown by Phase
    7.9 Top 20 Sponsors with Breakdown by Status
    7.10 Overview by Endpoint Status
    7.11 Overview by Race and Ethnicity
    7.12 Enrollment Data
    7.13 Top 20 countries for Trial Sites
    7.14 Top 20 Sites Globally
    7.15 Feasibility Analysis - Geographic Overview
    7.16 Feasibility Analysis - Benchmark Models
    8 Deals Landscape
    8.1 Mergers, Acquisitions, and Strategic Alliances by Region
    8.2 Recent Mergers, Acquisitions, and Strategic Alliances
    9 Commercial Assessment
    9.1 Key Market Players
    10 Future Market Catalysts
    11 Appendix
    11.1 Methodology
    11.2 Methodology - Sales Forecast
    11.3 Methodology - Pricing and Reimbursement
    11.4 Methodology - PTSR and LoA Analysis
    11.5 About the Authors
    11.6 Contact Us
    11.7 Disclaimer

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings